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ObesityAdipocytes play important roles in lipid storage, energy homeostasis and whole body insulin sensitivity. The
JAK–STAT (Janus Kinase–Signal Transducer and Activator of Transcription) pathway mediates a variety of phys-
iological processes including development, hematopoiesis, and inﬂammation. Although the JAK–STAT signaling
pathway occurs in all cells, this pathway canmediate cell speciﬁc responses. Studies in the last two decades have
identiﬁedhormones and cytokines that activate the JAK–STAT signaling pathway. These cytokines and hormones
have profound effects on adipocytes. The content of this review will introduce the types of adipocytes and im-
mune cells that make up adipose tissue, the impact of obesity on adipose cellular composition and function,
and the general constituents of the JAK–STAT pathway and how its activators regulate adipose tissue develop-
ment and physiology. A summary of the identiﬁcation of STAT target genes in adipocytes reveals how these tran-
scription factors impact various areas of adipocyte metabolism including insulin action, modulation of lipid
stores, and glucose homeostasis. Lastly, we will evaluate exciting new data linking the JAK–STAT pathway and
brown adipose tissue and consider the future outlook in this area of investigation. This article is part of a Special
Issue entitled: Modulation of Adipose Tissue in Health and Disease.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.1. Introduction
1.1. Adipocytes and adipose tissue
Obesity is a condition of excess adipose tissue and is the most
common metabolic disorder in the industrialized world. In the US
alone, it affects 154.7 million individuals over the age of 20, which
is approximately 25% of the adult population. This obesity epidemic
has been a prelude to increases in chronic diseases. Obese individuals,
particularly those with excess abdominal adipose tissue, have an ele-
vated risk of developing Type 2 diabetes mellitus (T2DM), cardiovas-
cular disease, and hypertension. During obesity, the production of
inﬂammatory cytokines and reactive oxygen species within adipose
tissue increases as well as ectopic lipid deposition in liver or skeletal
muscle (reviewed in [58]). These consequences reﬂect potential caus-
ative links between adipose tissue dysfunction and insulin resistance.dulation of Adipose Tissue in
rom the National Institutes of
, Department of Biological Sci-
A. Tel.: +1 225 763 2648; fax:
.V. Open access under CC BY-NC-SA licenseHowever, the exact nature of this relationship is still poorly under-
stood and the subject of intense investigation. Hence, understanding
adipose tissue biology is highly relevant in elucidating the pathogen-
esis and treatment of metabolic diseases like T2DM.
Adipocytes are highly specialized lipid storage cells that play a key
role in modulating energy balance and nutrient ﬂux in vertebrates.
They provide a storage reservoir for energy in the form of lipid, which
is stored as a single or multiple droplet(s) that give adipocytes their
characteristic roundedmorphological appearance. Adipocytes also pro-
duce and secrete numerous enzymes, hormones, cytokines, and growth
factors that modulate appetite, lipid and glucose homeostasis, insulin
sensitivity, inﬂammation, blood vessel formation, and overall energy
homeostasis [3]. Several of these secreted factors, such as leptin, prolac-
tin, interleukin-6, and cardiotrophin-1, activate the JAK–STAT pathway
and are mentioned in this review. In the context of this review, we also
discuss the STAT1-mediated transcriptional regulation of lipoprotein li-
pase, an enzyme secreted from adipocytes.
The two classical types of fat cells that have been widely studied in-
clude white and brown adipocytes. White adipocytes are important in
energy storage and have three main functions — they sequester and re-
lease lipid, take up glucose in response to insulin, and secrete paracrine
and endocrine factors. Brown adipocytes are predominantly classiﬁed
by their high content of mitochondria containing uncoupling protein-1
(UCP-1) and contribute to energy expenditure. UCP-1 uncouples the
electron transport chain from energy production and results in the re-
lease of potential energy obtained from food as heat. As a result, brown
adipocytes play an important role in adaptive thermogenesis and are.
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β3-adrenergic stimulation [23,75]. We will review two recent high im-
pact studies that link the JAK–STAT signaling pathway to brown adipo-
cyte differentiation and adaptive thermogenesis and mark the infancy
of our understanding of JAK–STAT signaling in brown adipose tissue
(BAT).
Expansion of adipose tissue occurs through both increases in the
size and number of the adipocyte population. New, mature adipo-
cytes arise via differentiation of progenitor cells within adipose tissue.
Evidence exists suggesting that white and brown adipocytes derive
from different types of mesenchymal progenitor cells [78]. However,
innovative studies examining the development of brown-like adipo-
cytes within white adipose tissue (WAT) recently have challenged
this concept [74]. The signaling factors regulating the transition of
mesenchymal progenitor cells to committed preadipocytes are poorly
deﬁned. Nonetheless, signiﬁcant advances towards an understanding
of adipose tissue biology have been made by studying the function of
transcription factors, which regulate differentiation of committed
preadipocytes, and are involved in the modulation of adipocyte
gene expression. Fat cell differentiation, known as adipogenesis, pro-
ceeds as a highly coordinated and temporally deﬁned series of events
that involves the regulated expression of numerous transcription fac-
tors (reviewed in [75,104]). Several laboratories have investigated
the role of STATs (Signal Transducers and Activators of Transcription)
in adipocyte development and function. Additionally, studies show
that many STAT activators play a critical role in the regulation of ad-
ipocyte gene expression and exhibit differential expression in condi-
tions of obesity and/or insulin resistance [13,75].
1.2. Other AT cell types
In addition to adipocytes, immune cells signiﬁcantly contribute to
the cellular composition of adipose tissue. Their presence within adi-
pose tissue is regulated by obesity and metabolic dysfunction. The pur-
pose of these immune cells and their relationship to metabolic
dysfunction within obese adipose tissue is the subject of intense inves-
tigation and debate. Whether their presence is a cause or consequence
with regard to insulin resistance is unknown, and both hypotheses
have been proposed. Some types of immune cells, such asmacrophages,
increase in obese adipose tissue, and are associated with inﬂammation
and metabolic disease. Yet the levels of eosinophils, which are anti-
inﬂammatory and associatedwith healthy adipose tissue, decrease dur-
ing obesity and insulin resistance (reviewed in [77]). Many studies sug-
gest that adipose tissue macrophages (ATMs) are associated with
insulin resistance in a manner that is dependent upon their activation
status. Yet, more recent studies suggest that ATMs may have house-
keeping functions in adipose tissue and may serve physiological roles
in modulating lipid ﬂux in adipocytes [47]. Interestingly, the JAK–STAT
pathwaywas ﬁrst identiﬁed and characterized as the result of immuno-
logical studies focused on understanding the signal transduction path-
way utilized by interferon gamma (IFNγ) (reviewed in [84]).
Interest in adipose tissue immune cells has prompted recent studies
examining the role of JAK–STAT activators and signaling in adipose tis-
sue immune cells. Several cytokines that are activators of the JAK–STAT
pathway are produced from immune cells, preadipocytes, and adipo-
cytes within adipose tissue and have paracrine and endocrine effects
on other cells with important functions in regulating metabolism and
energy balance. Little is known regarding the complex interplay of
JAK–STAT signaling between adipose tissue cells, but activators of this
pathway have been shown to regulate development and function of
both immune cells and adipocytes.
1.3. JAK–STAT signaling pathway
The STAT family of mammalian transcription factors is comprised
of seven members (STATs 1–4, 5A, 5B, and 6) that have cell andtissue-speciﬁc distribution that inﬂuences their speciﬁcity and function
[76]. STATs 5A and 5B, although highly homologous, are transcribed
from different genes. While the expression level of STAT5A relative to
STAT5B is tissue speciﬁc, the STAT5 proteins typically share similar pat-
terns of tissue-dependent gene expression. Intriguingly, they have been
shown to exhibit both redundant and non-redundant functions [94].
STATs are predominantly activated by phosphorylation of one tyrosine
residue near the C-terminus that is catalyzed by a Janus Kinase (JAK).
Members of the JAK family include JAKs 1–3 and Tyk2. The JAK–STAT
pathway is present in all cells, mediates the action of numerous cyto-
kines, growth factors, and hormones, and regulates diverse biological
functions, including immune responses, energy expenditure, and cellu-
lar differentiation. Under basal conditions, STATs are largely inactive
and localized to the cytoplasm. Upon ligand binding to a membrane-
bound receptor, the receptor-associated JAKs become activated and
phosphorylate tyrosine residues within the receptor, which then direct
recruitment of speciﬁc STATs. STATs bind the activated receptor via
their SH2 domains and become JAK substrates. Tyrosine phosphoryla-
tion of STATs results in the formation of homo- or hetero-dimers that
translocate to the nucleus where they regulate transcription of speciﬁc
target genes.
This review provides in depth coverage of the literature that relates
to the role of JAK–STAT signaling in adipogenesis. We also address the
ability of STATs to modulate fat cell function via transcriptional regula-
tion of adipocyte-speciﬁc gene targets in response to activator stimula-
tion. Additionally, we explore knockout studies of JAK–STAT activators
inmice. These studies suggest that JAK–STAT signaling in adipose tissue
plays an important role in paracrine communication between adipo-
cytes and AT immune cells that might inﬂuence the pathogenesis of
obesity. Lastly, we highlight novel studies regarding JAK–STAT signaling
in brown adipose tissue.
2. Regulation of adipogenesis by STAT proteins
The ﬁrst studies on the modulation of STATs during adipocyte devel-
opment were performed over ﬁfteen years ago and demonstrated that
protein levels of STATs 1, 3, 5A and 5B increased during 3T3–L1 fat cell
differentiation, providing the ﬁrst suggestion that these STAT proteins
may play a role in the transcriptional control of adipogenesis [86]. Five
years later, studies in subcutaneous human primary adipocytes con-
ﬁrmed the up regulation of STATs 3 and 5 during differentiation [32].
However, the pattern of STAT1 protein expression during human [32]
and murine [86] adipogenesis differed, suggesting species-speciﬁc
regulation. Decreased STAT1 expression during adipogenesis of human
adipocytes indicates that it does not promote human fat cell differentia-
tion. There are few studies that examine the role of STATs 1 and 3 in the
transcriptional control of adipogenesis. However, substantial in vitro and
in vivo evidence from over a dozen independent laboratories supports
the hypothesis that STAT5 promotes fat cell differentiation in mouse
and man.
2.1. The role of STAT5 proteins in adipocyte development
Studies of transgenic mice containing knockouts or deletions of
the STAT proteins have been critical in obtaining an understanding
of the function of these proteins in vivo. Deletion of STAT5A,
STAT5B, or both STAT5 proteins in genetically modiﬁed mice results
in impaired adipose tissue development with the double knockout
mice having fat pads only 20% of the normal size [94]. Since these
are non-inducible whole-body deletions of STAT5, it is unclear if the
reduced adipose tissue is related to developmental deﬁciencies. How-
ever, a recent study provides evidence that STAT5 proteins can pro-
mote adipocyte development in vivo in a mature animal. Fibroblasts
were genetically engineered to express STAT5A and injected into
athymic mice. STAT5A-expressing ﬁbroblasts conferred the formation
of ectopic fat pads and demonstrated that STAT5A is physiologically
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ter understanding of the ability of STAT5 to modulate endogenous
fat cell differentiation awaits the creation of transgenic mice in
which STAT5 is conditionally deleted or knocked out of only adipo-
cytes or adipose tissue. To date, a role of STAT5 in the development
of brown adipose tissue has not been explored.
Although in vivo studies are limited, numerous laboratories have in-
dependently demonstrated pro-adipogenic activity of STAT5 proteins
using multiple murine and human non-precursor and preadipocyte cell
types in culture. These studies have led to insights into the involvement
of STAT5 proteins in fat cell differentiation and the mechanisms by
which they promote adipogenesis, and the ﬁndings are summarized in
Fig. 1. In differentiating murine preadipocytes, the protein levels of both
STATs 5A and 5B are increased and tightly coupled to the development
of the lipid-bearing cellular phenotype and elevated expression of
well-studied adipogenic transcription factors, including C/AAAT enhanc-
er binding protein α (C/EBPα) and peroxisome proliferator-activator
receptor γ (PPARγ) [88]. Furthermore, ectopic expression of STAT5A in
non-precursor cells sufﬁciently induces fat cell differentiation [27,87]. In-
terestingly, STAT5B was unable to promote adipogenesis in non-
precursor cells, but it did enhance STAT5A-induced fat cell differentia-
tion, indicating distinct roles for STATs 5A and 5B in regulating
adipogenesis [27]. RNA interference studies support a supplementary
role of STAT5B in fat cell differentiation [38]. Studies using antisenseFig. 1. Roles of the JAK–STAT5 signaling pathway in adipose tissue. The JAK–STAT5 signaling
function of preadipocytes, adipocytes, and macrophages in adipose tissue. Substantial evide
adipogenesis. In mature adipocytes, multiple STAT5 target genes have been identiﬁed, dem
Studies also indicate that JAK–STAT5 signaling is important in the recruitment and developStat5 oligonucleotides as well as constitutively active and dominant-
negative STAT5 constructs have demonstrated that STAT5 proteins me-
diate the pro-adipogenic activity of growth hormone on preadipocytes
[39,79,108].
In several preadipocyte model systems, growth hormone (GH)-
activated STAT5 proteins have been shown to induce PPARγ expres-
sion suggesting that STAT5 can promote adipocyte differentiation by
regulating PPARγ [39]. This is supported by data showing that
STAT5 can directly bind and transactivate the PPARγ promoter
[39,55,100]. Many transcription factors have profound effects on adi-
pocyte development, but PPARγ is a critical transcriptional regulator
that is absolutely required for fat cell differentiation [6,61]. While the
evidence suggests that STAT5 proteins regulate PPARγ expression, it is
plausible that STAT5 also regulates the expression of proteins responsi-
ble for making PPARγ ligands or other proteins important in the deve-
loping and mature adipocyte.
STAT5 proteins are speciﬁcally activated by tyrosine phosphorylation
almost immediately following induction of adipogenesis in 3T3–L1 cells
[6,61]. Interestingly, cooperative binding of C/EBPβ and STAT5A occurs
during a very early stage of adipogenesis and suggests that STAT5A is in-
volved in chromatin remodeling and priming of regulatory sites for
subsequent binding by other transcription factors [82]. Intriguingly, in
human bone marrow-derived stromal cells induced to undergo
adipogenesis, PPARγ also binds to the STAT5A promoter while C/EBPαpathway is activated by GH, PRL, and GM-CSF, and it regulates the development and/or
nce supports that STAT5 proteins are activated in preadipocytes and that they promote
onstrating a role for STAT5 in modulating key physiological properties of adipocytes.
ment of adipose tissue macrophages.
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complex interplay of STAT5 proteins with other adipogenic transcrip-
tional regulators to orchestrate the stages of differentiation leading to
the biochemical and morphological changes associated with the mature
lipid-laden fat cell.
Although the majority of studies suggest that STAT5 proteins pro-
mote adipogenesis, there is some confounding data. For example,
STAT5 activators such asGH and oncostatinM (OSM) can repress adipo-
cyte differentiation in cell culture models of precursor cells from mice
[57], rats [70], and humans [83]. This anti-adipogenic activity of STAT5
can likely be attributed to speciﬁcs of OSM signaling [57], possibly via
modulation of post-translational modiﬁcations of STAT5 and/or its
interacting protein partners. For studies inwhich primary preadipocytes
[70,83] or mouse embryonic ﬁbroblasts [57] – versus committed
preadipocyte cell lines – were used to assess adipogenic potential, the
developmental stage of the cell and how far it is committed to develop
into an adipocyte might be responsible for the opposing effects of
STAT5 on adipogenesis. Other factors could include species-speciﬁc dif-
ferences in rat primary preadipocytes in response to GHor pre-exposure
of the primary preadipocytes to GH in vivo [70]. Nonetheless, STAT5
proteins, particularly STAT5A, play an important role in regulating
adipogenesis, and the preponderance of evidence suggests that they
are pro-adipogenic in most model systems.
2.2. The role of STAT1 in adipocyte development
STAT1 expression is induced during adipocyte development in
mouse cells [86]. However, mice with a targeted disruption of the
Stat1 gene do not exhibit differences in weight gain, and with the ex-
ception of IFN-dependent responses, biologic responses to other cyto-
kines were not defective [56]. Interestingly, IFNγ inhibits adipogenesis
of SGBS (Simpson–Golabi–Behmel syndrome) human fat cells [53]
and rodent preadipocytes [30,40]. Although the direct role of STAT1 in
the anti-adipogenic action of IFNγ was not investigated, experiments
using pharmacological inhibitors indicate that the JAK–STAT1 pathway
plays a central role in the ability of IFNγ to induce insulin resistance, de-
crease triglyceride stores, and down-regulate expression of lipogenic
genes in mature human fat cells [53]. IFNγ also activates JAK2–STAT3
[4,53,85]. However, speciﬁc inhibition of JAK2 did not block IFNγ effects
on fat cell development and physiology, and leptin-induced activation
of JAK2–STAT3 failed to substantially decrease adipocyte differentiation
and lipid accumulation [53]. Thus, it was concluded that JAK1–STAT1
primarily mediated the substantial IFNγ-induced modulation of
human adipocyte functions [53].
IFNγ-null mice fed a high fat diet have smaller adipocytes in visceral
WAT than wild-type mice [65]. Interestingly, there were no differences
in body weight [65] similar to the STAT1 null mice on chow diet [56].
Together the presence of smaller adipocytes and lack of change in
body weight in the IFNγ knockout mice suggest an increase in fat cell
differentiation and indicate that IFNγ might play an inhibitory role in
adipogenesis in vivo. An increase in adipocyte cell number in the
IFNγ-null mice would have better supported a claim of increased
adipogenesis; however, this parameter is difﬁcult to measure and was
not assessed in the study.
Knockout of IFNγ also decreased the size of the natural killer (NK)
cell population in visceral but not subcutaneous WAT, while it shifted
the activation phenotype of ATMs from M1 to M2 in both depots [65].
M1-type ATMs produce inﬂammatory cytokines that are correlated
with the development of insulin resistance in obesity. Amultitude of re-
ports demonstrate an association between immune cell inﬁltration in
visceral but not subcutaneous adipose tissue during obesity. Thus, it is
not surprising that knockout of IFNγ results inmore substantial changes
in the population of immune cells in visceralWAT. Accordingly, it is pos-
sible that IFNγ indirectly modulates adipogenesis via its effects on the
composition of immune cells within adipose tissue. The studies of
IFNγ-null mice indicate that IFNγ plays a role during obesity in theregulation of inﬂammation and insulin sensitivity through several prob-
able mechanisms such as modulating adipogenesis and inﬂuencing the
size and composition of the AT immune cell population. However, the
role of JAK–STAT1 signaling inmediating these effects of IFNγ in obesity
remains to be elucidated.
The ability of IFNγ and JAK–STAT1 signaling to regulate fat cell dif-
ferentiation has also been studied in the context of crosstalk with the
hedgehog signaling pathway. The hedgehog signaling pathway consti-
tutes an ancestral developmental process important in the regulation
of stem cell differentiation during embryonic development and adult
tissue homeostasis [7,37,98]. Sonic hedgehog (Shh) is the most widely
studied homolog of the three mammalian hedgehog proteins. Shh sig-
naling speciﬁcally blocks adipogenesis in white, but not brown adipose
tissue [69,92]. IFNγ inhibits fat cell differentiation in the absence of Shh
signaling [30,40,96]. However, when the Shh pathway is activated in
various preadipocyte model systems, IFNγ blocks Shh signaling and
rescues adipogenesis via a JAK–STAT1-dependent mechanism [96].
IFNγ-mediated inhibition of Shh signaling did not occur in Stat1−/−
mouse embryonic ﬁbroblasts (MEFs), indicating that the crosstalk de-
pends on Stat1. Thus, STAT1 appears to regulate adipocyte differentia-
tion via crosstalk with the Shh signaling pathway.
Collectively, these ﬁndings suggest that STAT1 may not play a major
role in adipocyte differentiation and adipose tissue development under
“normal” conditions in lean subjects. However, in the context of high
fat diet (HFD)-induced obesity when IFNγ levels are elevated as a result
of increased numbers of activated IFNγ-producing immune cells inﬁltrat-
ing visceral adipose tissue, JAK–STAT1 signaling may play an inhibitory
role in the control of adipocyte differentiation. Further studies using ge-
neticmanipulation of Stat1 expression in adipocytes are needed to better
elucidate the role of STAT1 in the control of adipogenesis in vivo. Addi-
tionally, it would be interesting to examine the phenotype of adipose tis-
sue in Stat1 null mice following the development of diet induced obesity.
Based on the available data, it seems that cross-talk with other signaling
pathways and the inﬂammatory state of adipose tissue are important fac-
tors modulating the ability of STAT1 to regulate adipogenesis.
2.3. Role of STAT3 in the regulation of adipogenesis
The JAK2–STAT3 pathway is activated early during adipogenesis
[18,101,109] and is involved in achievingmaximal adipocyte differenti-
ation potentially through modulation of C/EBPβ transcription [109]. As
demonstrated by in vitro experiments, adipogenesis is suppressed by
selective inhibition of JAK2 or STAT3, siRNA-induced knock-down of
STAT3, or overexpression of dominant-negative STAT3 [101]. PIAS3,
protein inhibitor of activated STAT3, is constitutively expressed in
3T3–L1 cells, and its activation represses STAT3 activity and inhibits
fat cell differentiation [16]. In addition, a PPARγ synthetic agonist res-
cues adipogenesis following RNAi-induced knock-down of STAT3,
suggesting that STAT3 regulation of adipocyte differentiation occurs up-
stream of PPARγ activation [101]. Collectively, these studies indicate
that activation of the JAK2–STAT3 signaling pathway plays a role in
themodulation of adipogenesis. Additional studies have shown that ac-
tivation of STAT3may promote fat cell differentiation viamodulation of
mitotic clonal expansion, a proliferative phase that occurs immediately
following induction of adipogenesis and is necessary for differentiation
of 3T3–L1 fat cells [11,18,51].
Since germ-line deletion of STAT3 is embryonic lethal [44,49], stud-
ies are lacking to demonstrate that STAT3 modulates adipocyte differ-
entiation in vivo. However, there is a transgenic mouse model where
STAT3 expressionwas knocked outwith use of aP2 Cre. The aP2 protein
is a lipid binding protein that is highly expressed in fat cells and is likely
the most abundantly expressed protein in mature adipocytes. The pri-
mary phenotype of the aP2 Cre-driven STAT3 knockout mouse was in-
creased weight and increased adipose tissue mass, associated with
adipocyte hypertrophy [10]. These studies suggest that STAT3 contrib-
utes to body weight homeostasis. However, since aP2 can also be
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cells [97], it is unclear if these observations are solely mediated by the
lack of STAT3 in adipocytes. Furthermore, since aP2-driven deletion of
STAT3 does not occur until late adipogenesis, the observed adipocyte
hypertrophy is not likely a result of direct effects of STAT3 on fat cell dif-
ferentiation. Overall, evidence suggests that STAT3 is capable of modu-
lating adipogenesis. However, further investigations probing JAK–
STAT3 signaling at various stages of adipogenesis in vitro and in vivo
are necessary to better understand the ability of STAT3 to regulate adi-
pocyte and adipose tissue development.
3. Role of JAKs in adipocyte development and function
Although STATs have been fairly well studied in adipocytes, there
areminimal studies focusing on JAK expression, activation, and function
in fat cells and adipose tissue. JAK kinases are largely controlled by tyro-
sinephosphorylation, rather than by expression levels. The ubiquitously
expressed JAKs 1 and 2 are present at similar levels in preadipocytes
and adipocytes [88], and they are expressed in adipose tissue in vivo
[33]. There is some evidence that Tyk2 and JAK3 are expressed in adi-
pose tissue [19,33]. As indicated earlier, adipose tissue is comprised of
many cell types and there is no data to suggest that these two JAK family
members are expressed in white adipocytes.
Both preadipocytes and adipocytes are responsive to hormones and
growth factors which activate JAKs 1 and 2, including GH, prolactin (PRL),
IFNγ, leukemia inhibitory factor (LIF), OSM, cardiotrophin-1 (CT-1), and cil-
iary neurotrophic factor (CNTF) [4,24,39,53,66,85,90,110-112]. Currently,
there is no evidence that JAKs play a STAT-independent role inmodulating
adipocyte differentiation in white adipose tissue. However, several
cytokines that inhibit adipogenesis, including IFNγ [30,40], OSM
[57,83], and neuropoietin (NP) [104], are potent activators of JAK ki-
nases. To date, only JAKs 1 and 2 have been detected in white adipo-
cytes and their roles are solely attributed to their ability to be
activated by cytokines and confer STAT activation. There is one ex-
ception, however, in which JAK2 was shown to physically associate
with aP2 in adipocytes [95]. The unphosphorylated form of JAK2
has been shown to interact with aP2 and the results of this study sug-
gest that ligand-bound aP2 decreases JAK2 signaling [95]. Overall,
there is a paucity of data regarding the role of JAKs in adipocytes.
Hence, additional studies will be required to further elucidate the
STAT-dependent and/or independent functions of these kinases in
fat cells.
4. STAT target genes in preadipocytes and adipocytes
The regulation of tissue-speciﬁc genes has been shown to be a phys-
iological role of STAT proteins in a variety of cell types, including adipo-
cytes. To date, speciﬁc target genes have been identiﬁed for STATs, 1, 5A,
and 5B, but not for STATs 3 and 6, in adipocytes (Table 1). The STAT tar-
get genes elucidated in fat cells code for proteins that regulate adipocyte
development, insulin action, and lipid and carbohydratemetabolism. As
summarized in Fig. 1, many laboratories around the world have shown
a role for STAT5 proteins in adipocyte and adipose tissue developmentable 1
TAT target genes in preadipocytes and adipocytes.
Cell type STAT STAT activator Target gene 
Preadipocyte 
STAT5 Unknown PPARγ
STAT3 Unknown C/EBPβ
Adipocyte 
STAT1 
IFNγ PPARγ
IFNγ LPL 
STAT5 
GH aP2 
GH AOX 
GH, PRL FAS 
GH, PRL PDK4 T
Sin vitro and in vivo. Hence, it is not surprising that STAT5 can directly
bind the PPARγ3 promoter [55] and can transactivate the PPARγ2 and
PPARγ3 promoters [39,55]. PPARγ is a STAT5 target gene during adipo-
cyte development and its modulation by STAT5 likely plays a role in the
ability of STAT5 to promote adipocyte differentiation in vitro and in vivo.
Studies have shown that PPARγ is also a STAT1 target gene in adipo-
cytes. In 3T3–L1 adipocytes, STAT1 homodimers bind to an IFNγ
responsive site within the PPARγ2 promoter and suggest that IFNγ-
induced repression of PPARγ2 transcription [99] is mediated by the di-
rect action of STAT1 on the PPARγ2 promoter [34]. Of note, a dominant
negative mutation in PPARγ and IFNγ signaling have been associated
with the development of insulin resistance [5,53,99]. Consequently,
STAT1 likely mediates the ability of IFNγ to induce insulin resistance
[46,53,80,99] and inhibit adipogenesis [30,40] via transcriptional repres-
sion of PPARγ. An IFNγ-sensitive binding site for STAT1 was also discov-
ered in the murine lipoprotein lipase (LPL) promoter [35]. LPL is the
rate-limiting enzyme that catalyzes the hydrolysis of serum triglycerides
from lipoproteins into free fatty acids for uptake and storage in adipose
tissue. IFNγ-activated STAT1 binds to the LPL promoter in a manner
that is consistent with IFNγ-induced repression of LPL expression and in-
hibition of LPL activity in murine adipocytes [20,30]. While STAT3 is also
induced in response to IFNγ, STAT1 is amore robustmediator of IFNγ sig-
naling in murine and human adipocytes [4,53,85]. In the described stud-
ies, STAT3 was unable to bind to the STAT1 binding sites within the
PPARγ promoter [34], and LIF, a potent STAT3 activator, did not confer
binding of STAT3 to the IFNγ sensitive region of the LPL promoter [35].
Since STAT5 proteins are activated early during adipocyte differenti-
ation and have been shown to play such a key role in adipocyte devel-
opment, it is not surprising that most studies have focused on the
functions of STAT5 proteins in mature adipocytes. The promoter for
acyl CoA oxidase (AOX), the rate limiting enzyme in peroxisomal fatty
acid β-oxidation, contains a STAT5 binding site that modulates its
gene expression in fat cells [12]. Transfection studies have shown that
the promoter activity of aP2, an abundantly expressed lipid binding pro-
tein in fat cells, can be activated by STAT5 [60]. Other studies have
shown that STAT5 mediates the inhibition of aP2 expression in rat pri-
mary preadipocytes [70]. This was the ﬁrst study to suggest that
STAT5 proteins could act as transcriptional repressors. Since that time,
our own research has revealed that STAT5A can act as a transcriptional
repressor in adipocytes. A STAT5A binding site in the murine fatty acid
synthase (FAS) promoter mediates the repression of FAS transcription
that occurs with growth hormone (GH) or prolactin (PRL) treatment
[36]. FAS catalyzes the production of long chain fatty acids and is a cru-
cial enzyme involved in de novo lipogenesis. In addition to modulation
of genes associated with lipid metabolism such as AOX and FAS,
STAT5 can also increase the transcription of pyruvate dehydrogenase ki-
nase (PDK)-4, a known regulator of glycolysis that is highly induced in
adipocytes by PRL or GH in a STAT5 dependent manner [103]. Under
these conditions, insulin resistance accompanies the induction of
PDK4. It is well known that PRL and GH are important modulators of
lipid metabolism and are also potent inducers of STAT5 in adipocytes
[4,60]. Hence, many of the metabolic actions of these anterior pituitary
hormones could be controlled by direct modulation of target genes by
STAT5 (Table 1).We also have data to indicate that STAT5 proteins reg-
ulate the expression of adiponectin, an important adipocyte hormone
that modulates insulin sensitivity. In summary, STAT5 transcriptionally
regulates the expression of AOX, aP2, FAS, PDK4, and adiponectin —
proteins that modulate lipid and glucose metabolism and insulin sensi-
tivity in fully differentiated fat cells (Fig. 1). Although relatively few
STAT5 target genes have been identiﬁed in adipocytes, it is logical to
predict that other STAT5A target genes that play a role in lipid or glucose
metabolism will be identiﬁed.
STAT3 is abundantly expressed in adipocytes [32,86] and mediates
the action of numerous cytokines in fat cells. However, with the ex-
ception of C/EBPβ as a potential STAT3 gene target activated early in
the adipogenic program [109], to date no adipocyte-speciﬁc direct
436 A.J. Richard, J.M. Stephens / Biochimica et Biophysica Acta 1842 (2014) 431–439target genes have been identiﬁed for STAT3 (Table 1). Although
STAT6 is equivalently expressed in preadipocytes and throughout
fat cell differentiation [86], only IL-4 has been shown to activate this
transcription factor in 3T3–L1 preadipocytes but not in adipocytes
[17]. Thus, activators, functions, and gene targets of STAT6 in both
preadipocytes and adipocytes remain to be elucidated. Overall, there
is almost nothing known about the identity of STAT3 and STAT6 tar-
get genes in adipocytes.
5. JAK–STAT signaling in AT immune cells
The JAK–STAT pathway was ﬁrst elucidated from immunological
studies in the early 1990s that were investigating cell-speciﬁc IFNγ-
responsive gene transcription [84]. In the past two decades, investiga-
tors have generated a wealth of information regarding activators and
functions of the JAK–STAT pathway in immune cells, inﬂammation,
and inﬂammatory disorders [68,84]. Research over the past decade
has established AT as a bona ﬁde endocrine organ comprised of a hetero-
geneous population of preadipocytes, adipocytes, endothelial cells, con-
nective tissue, and immune cells.Multiple lines of evidence suggest that
alterations in the phenotype and/or number of AT-resident immune
cells are associated with the development of insulin resistance in
obese mice and humans [77]. Currently, there are only a few studies
that examine activators and functions of the JAK–STAT signaling path-
way in the context of AT and immunometabolism, an emerging ﬁeld
of investigation linking immunology and metabolism [52,77]. In this
section, we discuss the ability of two known JAK–STAT activators,
GM-CSF (granulocyte-macrophage colony-stimulating factor) and
IFNγ, to modulate adipose tissue function.
STAT5 plays a role in the differentiation of myeloid cells and activa-
tion of macrophages [106]. GM-CSF is a proinﬂammatory cytokine that
signals via the JAK2–STAT5 signaling pathway [21,59,73,102]. GM-CSF
knockout mice fed a HFD have increased adiposity and adipocyte size
[42]. Analysis of these mice suggests that the presence of GM-CSF posi-
tively correlates with the relative number of macrophages within the
mesenteric fat and the relative expression of GM-CSF differs among
the fat depots. In the absence of GM-CSF, the number of ATMs inmesen-
teric fat declined and was accompanied by decreased expression of
pro-inﬂammatory cytokines in mice fed a high fat diet. Additionally,
GM-CSF null mice were protected from HFD-induced insulin resistance
despite increased adiposity [42]. The exact mechanisms underlying the
correlation between increased adiposity, adipose tissue dysfunction,
and insulin resistance are active areas of investigation. Other exam-
ples [41,43], including these ﬁndings with the GM-CSF knockout mice
[42], seem to rule out increased adipocyte size as the causative factor
in the relationship between AT dysfunction and insulin resistance. Cur-
rently, it is not knownwhether STAT5mediates these effects of GM-CSF
in AT, as both STATs 1 and 3 also can be activated by this cytokine [9].
Interestingly, STAT5 signaling in hypothalamic nuclei of the brain has
been implicated in the ability of GM-CSF to regulate food intake and
body adiposity [48]. Overall, these data indicate that GM-CSF plays an
important role in AT to recruit and activate macrophages that contrib-
ute to AT inﬂammation, and these actions of GM-CSF are likely mediat-
ed by the JAK–STAT signaling pathway (Fig. 1).
IFNγ is produced from both natural killer (NK) cells [64] and T
cells [22,71,91,107] present in adipose tissue. IFNγ can inhibit the dif-
ferentiation of preadipocytes [30,40], induce insulin resistance in ma-
ture adipocytes [53,99], and decrease PPARγ expression by targeting
this nuclear receptor to the ubiquitin proteasome system for degrada-
tion in adipocytes [26]. It is highly likely that the production of IFNγ
from inﬁltrated immune cells acts in a paracrine fashion on adjacent
adipocytes to result in insulin resistance. Interestingly, deletion of
IFNγ in transgenic mice shifted the activation of ATMs in visceral
WAT toward an alternatively activated phenotype that was associat-
ed with decreased production of inﬂammatory cytokines and im-
proved insulin sensitivity [65].Numerous other JAK–STAT activators are produced in adipose tissue
and likely act in a paracrine manner to regulate the development and
function of immune cells and adipocytes. For instance, IL-1 and IL-6
are secreted fromATMs [54]. Themajority of IL-4 in adipose tissue is re-
leased from eosinophils, and as discussed in the next section signals via
JAK–STAT6 tomodulate the function of BAT andWAT [63]. Prolactin and
leptin, although they also act as endocrine hormones, have direct ac-
tions on immune and fat cells in adipose tissue [2,24,25,81].
In addition to macrophages, T cells, and NK cells that have already
been mentioned, recent prominent studies have also examined the
roles of B cells [15,105], mast cells [1,50], and neutrophils [93] inmediat-
ing insulin resistance associated with obesity. B cells, mast cells and
neutrophils have all been shown to increase in number and/or shift acti-
vation status within adipose tissue upon feeding mice HFD [1,93,105].
Using genetic knockout, immuno-neutralization, or pharmacological in-
activation techniques, loss of any of these immune cells or their direct
mediators, such as elastase for neutrophils, was associated with
improved insulin sensitivity. Similarly, attempts to increase B cells,
neutrophils, or mast cells correlate with increased insulin resistance
[50,93,105], thus establishing these immune cells as modulators of insu-
lin resistance. To date, no studies have examined the role of the JAK–
STAT pathway inmediating the action of B cells or neutrophils in adipose
tissue. However, it was shown that mast cells promote angiogenesis in
AT in an IL-6 and IFNγ-dependent manner [50]. Activation of the JAK–
STAT pathwayswas not assessed in these studies; therefore, future stud-
ies are needed to evaluate the role of this pathway inmast cell action. As
the immunometabolism ﬁeld continues to develop, we propose that fu-
ture studies of JAK–STAT signaling within adipose tissue will be an excit-
ing new area of research that will lead to additional insights into the
mechanism(s) by which AT immune cells communicate with adipocytes
and/or other AT immune cells to modulate insulin sensitivity.
6. Emerging roles of the JAK–STAT pathway in brown adipose
tissue
The last few years have been accompanied by a large increase in
studies on BAT. Although originally thought to be absent in adult
humans, there is now evidence to support the presence of BAT and
its association with metabolic health [14,62]. In addition, many trans-
genic mouse models have been generated that strongly suggest that
increased BAT mass is associated with increases in energy expendi-
ture that are associated with improvements in metabolic health [8].
The opposite is also true, and mice lacking BAT are obese and have
metabolic impairments [31,45]. In the last few months, two high im-
pact studies have linked the JAK–STAT signaling pathway to BAT, and
these ﬁndings are summarized in Fig. 2. It is largely accepted that
macrophages in WAT play a role in the pathogenesis of insulin resis-
tance and T2DM (reviewed in [72]). It is not clear whether macro-
phages in BAT are also important, and this topic is controversial.
However, a recent study clearly demonstrates the presence of AAMs
(alternatively activated macrophages) in BAT [63]. These macro-
phages are sensitive to IL-4, which acts via the JAK–STAT6 signaling
pathway. The activation of this pathway results in the production of
norepinephrine (NE). Among other physiological effects, NE can activate
lipolysis in WAT. The hypothesis developed from these recent studies
suggests that NE produced from alternatively activated macrophages in
BAT acts on WAT to modulate free fatty acid levels (Fig. 2). The use of
IL-4 receptor null mice and STAT6 null mice reveals that these proteins
are necessary for adaptive thermogenesis [63].
Another study linking BAT with the JAK–STAT pathway provides
evidence that the JAK kinase Tyk2 plays an important role in BAT de-
velopment. In vitro studies strongly provide evidence that Tyk2 pro-
motes adipogenesis. Moreover, Tyk2 null mice are obese and have
impaired glucose tolerance. The phenotype of these mice can be res-
cued by aP2 driven expression of a constitutively active STAT3 protein
[19]. In summary, this study suggests that the Tyk2–STAT3 signaling
Fig. 2. JAK–STAT signaling in white and brown adipose tissues. Different transcriptional programs control the adipogenesis of white and brown adipocytes, and different JAK and
STAT members have been implicated in these programs. Cytokine and hormone activators of the JAK–STAT pathway are produced and utilized by various cell types present within
adipose tissue to modulate the physiological function of WAT and BAT.
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are the ﬁrst two studies to indicate the potential importance of the
JAK–STAT signaling pathway in regulating the production and func-
tion of BAT.7. Conclusions and outlook
In conclusion,modulation of the JAK–STAT pathway can regulate ad-
ipocyte development and function. An emerging area of investigation
linking JAK–STAT signaling and adipocyte function will clearly be stud-
ies that examine the interplay of immune cells and adipocytes in both
brown and white adipose tissues. Additional studies in both cultured
adipocytes and in adipose tissue will be needed to reveal comprehen-
sive roles of the JAK–STAT family members in adipocytes, obesity, and
insulin resistance. Although tyrosine phosphorylation is critical for ca-
nonical STAT activation, other covalent modiﬁcations such as serine
phosphorylation, acetylation, methylation and sumoylation can also
occur (reviewed in [84]), and studies of these STAT modiﬁcations are
in their infancy. Moreover, the non-canonical mechanisms and func-
tions of JAKs and STATs in adipocytes have not been well studied. Re-
cent investigations indicate that STATs can participate in chromatin
organization and mitochondrial respiration in ways that are indepen-
dent of transcriptional regulation. All of these topics will likely be in-
tense areas of investigation in adipocyte biology in the near future
and will hopefully lead to the identiﬁcation of new therapeutic targets
for metabolic diseases.References
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